Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · Healing & Recovery

LL-37 vs Thymosin-α1

LL-37 and Thymosin-α1 are both immune-facing peptides, but at different ends of the response. LL-37 is a direct antimicrobial effector of the innate immune system. Thymosin-α1 is an adaptive-immunity modulator that drives T-cell maturation.

Bangkok research desk ·

Side-by-side

LL-37 Thymosin-α1
MechanismAntimicrobial cathelicidin fragment; innate immune effector.T-cell maturation; adaptive-immunity enhancement; Th1 polarisation.
Half-lifeShort plasma, local tissue activity.~2 hours plasma; persistent downstream effects.
Dose100-500 mcg/day SC (research-dependent).1.6 mg twice weekly SC.
CycleResearch-dependent.4-8 weeks typically.
Research contextAntimicrobial and wound-healing research; cautioned in autoimmune contexts1.Registered clinical use in hepatitis B and oncology adjuvant; strong human data2.
Cost tierMid.Mid-to-high.

LL-37 and Thymosin-α1 sit on opposite sides of the immune system. LL-37 is a cathelicidin-derived antimicrobial peptide. It kills bacteria, viruses, and fungi directly at the tissue level and signals through formyl peptide receptors to modulate local inflammation1. Thymosin-α1 does not kill pathogens; it orchestrates the adaptive response by driving T-cell maturation and polarising Th1 cytokines2.

Clinical registration is where the two diverge most sharply. Thymosin-α1 is registered in over 30 countries for hepatitis B and is widely used as an oncology adjuvant. Its dosing, safety profile, and endpoints are well-characterised in human trials. LL-37 remains primarily a research peptide; the endogenous peptide is a well-studied component of innate immunity, but synthetic LL-37 as a therapeutic is still early-stage.

Research use typically separates them. A researcher studying chronic wound infection, biofilm disruption, or the interface between innate immunity and healing works with LL-37. A researcher studying chronic viral infection, immune reconstitution, or cancer immunotherapy adjunct works with Thymosin-α1. Stacking is uncommon because the endpoints rarely overlap.

LL-37 research should account for autoimmune contraindications; the peptide's pro-inflammatory signalling has been implicated in lupus and psoriasis pathology. Thymosin-α1's principal caution is ongoing immunosuppressive therapy. See the broader category view in best peptides for healing and recovery.

Frequently asked

Which has stronger human clinical data?
Thymosin-α1 has far stronger human data. It is registered for hepatitis B and used as an oncology adjuvant in more than 30 countries2. LL-37 synthetic is primarily a research compound.
Can they be combined?
Combination is uncommon. The mechanisms solve different problems (innate vs adaptive immunity), and stacking rationale rarely appears in the literature.
What are the key contraindications?
LL-37 warrants caution in autoimmune conditions. Thymosin-α1 warrants caution when concurrent immunosuppressive therapy is active.
Research desk
Ordering both LL-37 and Thymosin-α1 for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Vandamme D, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012. PMID: 23246832
  2. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016. PMID: 27450734

All references verified against PubMed via NCBI E-utilities.